Intra-Cellular Therapies Reports Second Quarter 2024 Financial Results, Provides Corporate Update and Raises 2024 CAPLYTA Sales Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. SPCX
2. FDX
3. ABBV
4. META
5. SPY
6. ACN
7. BLZE
8. IBM
9. NKE
10. MU

Go back to Intra-Cellular Therapies Reports Second Quarter 2024 Financial Results, Provides Corporate Update and Raises 2024 CAPLYTA Sales Guidance

Intra-Cellular Therapies (ITCI) PT Lowered to $106 at RBC Capital

August 8, 2024 6:23 AM EDT

RBC Capital analyst Brian Abrahams lowered the price target on Intra-Cellular Therapies (NASDAQ: ITCI) to $106.00 (from $107.00) while maintaining a Outperform rating.

The analyst comments "Caplyta continues to grow in its approved indications and with MDD filings and data presentations on track... More